Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Moodys
Covington
McKinsey
Fuji
Accenture
Cantor Fitzgerald
Mallinckrodt
Daiichi Sankyo

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,637,553

« Back to Dashboard

Which drugs does patent 8,637,553 protect, and when does it expire?

Patent 8,637,553 protects STIVARGA and is included in one NDA.

This patent has sixty patent family members in thirty-eight countries.
Summary for Patent: 8,637,553
Title:Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Abstract: A compound of Formula (I): ##STR00001## salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.
Inventor(s): Boyer; Stephen (Hilden, DE), Dumas; Jacques (Bethany, CT), Riedl; Bernd (Wuppertal, DE), Wilhelm; Scott (Orange, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Application Number:10/895,985
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,637,553
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,637,553

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,637,553

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1663978 ➤ Try a Free Trial
New Zealand 580384 ➤ Try a Free Trial
New Zealand 544920 ➤ Try a Free Trial
Norway 335323 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Dow
McKesson
QuintilesIMS
Johnson and Johnson
Merck
Cipla
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.